All Stories

  1. HCV NS5A replication complex inhibitors

    Article • Current Opinion in Pharmacology, October 2016, Elsevier

    Mr Donald R O'Boyle II

  2. Making a good drug better

    Article • Antimicrobial Agents and Chemotherapy, December 2015, ASM Journals

    Mr Donald R O'Boyle II

  3. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A

    Article • Nature, November 2015, Nature

    Mr Donald R O'Boyle II

  4. Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors

    Article • Journal of Medicinal Chemistry, March 2014, American Chemical Society (ACS)

    Mr Donald R O'Boyle II

  5. HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity

    Article • Journal of Medicinal Chemistry, March 2014, American Chemical Society (ACS)

    Mr Donald R O'Boyle II

  6. Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir

    Article • Journal of Medicinal Chemistry, March 2014, American Chemical Society (ACS)

    Mr Donald R O'Boyle II

  7. A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir

    Article • Journal of Virological Methods, October 2013, Elsevier

    Mr Donald R O'Boyle II

  8. Characterizations of HCV NS5A replication complex inhibitors

    Article • Virology, September 2013, Elsevier

    Mr Donald R O'Boyle II

  9. HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives

    Article • Bioorganic & Medicinal Chemistry Letters, August 2013, Elsevier

    Mr Donald R O'Boyle II

  10. HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies

    Article • Bioorganic & Medicinal Chemistry Letters, February 2013, Elsevier

    Mr Donald R O'Boyle II

  11. HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides

    Article • Bioorganic & Medicinal Chemistry Letters, October 2012, Elsevier

    Mr Donald R O'Boyle II

  12. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

    Article • Hepatology, May 2012, Wiley

    Mr Donald R O'Boyle II

  13. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

    Article • Hepatology, December 2011, Wiley

    Mr Donald R O'Boyle II

  14. Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes

    Article • ACS Medicinal Chemistry Letters, March 2011, American Chemical Society (ACS)

    Mr Donald R O'Boyle II

  15. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

    Article • Nature, April 2010, Nature

    Mr Donald R O'Boyle II

  16. Multiplexing cell based assays

    Article • Antimicrobial Agents and Chemotherapy, April 2005, ASM Journals

    Mr Donald R O'Boyle II

  17. Functional Conservations of the Alkaline Nuclease of Herpes Simplex Type 1 and Human Cytomegalovirus

    Article • Virology, September 1998, Elsevier

    Sandra K Weller, Mr Donald R O'Boyle II

  18. Identification of a Novel Peptide Substrate of HSV-1 Protease Using Substrate Phage Display

    Article • Virology, September 1997, Elsevier

    Mr Donald R O'Boyle II

  19. Stimulation of the Herpes Simplex Virus Type I Protease by Antichaeotrophic Salts

    Article • Journal of Biological Chemistry, December 1995, American Society for Biochemistry & Molecular Biology (ASBMB)

    Mr Donald R O'Boyle II

  20. The Effect of Internal Autocleavage on Kinetic Properties of the Human Cytomegalovirus Protease Catalytic Domain

    Article • Journal of Biological Chemistry, March 1995, American Society for Biochemistry & Molecular Biology (ASBMB)

    Mr Donald R O'Boyle II

  21. Substrate requirements of the HSV-1 and CMV proteases in vitro using peptides derived from their maturation and release sites

    Article • January 1995, Springer Science + Business Media

    Mr Donald R O'Boyle II

  22. In vitro Proteolytic Activity and Active-Site Identification of the Human Cytomegalovirus Protease

    Article • FEBS Journal, December 1994, Wiley

    Mr Donald R O'Boyle II

  23. 67 Identification of the specific serine residue at the active site of the herpes simplex virus type 1 protease

    Article • Antiviral Research, February 1994, Elsevier

    Mr Donald R O'Boyle II

  24. Restriction Endonuclease Patterns of Cytomegalovirus After Passage in Humans

    Article • The Journal of Infectious Diseases, February 1987, Oxford University Press (OUP)

    Mr Donald R O'Boyle II